Form 4: Provectus CEO Converts Debt to Equity

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note.
• The conversion occurred on September 19, 2025, as an automatic conversion twelve months after the note's issue date.
• The 2024 Note, with a principal amount of $100,000, was converted into 37,760 shares of Series D-1 Convertible Preferred Stock.
• The conversion price for the Series D-1 Preferred Stock was $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.
• Following this transaction, Edward Pershing beneficially owns 2,418,447 shares of Common Stock, including those underlying the preferred stock.

Sentiment

Score: 6

Explanation: The conversion of debt to equity is generally viewed as a positive for the company's balance sheet by reducing liabilities. While it introduces future dilution risk, it also demonstrates continued insider commitment.

Positives

• Conversion of debt to equity reduces the company's outstanding debt, which can improve its balance sheet.
• Increased insider ownership (indirectly through preferred stock) may signal management's continued confidence in the company's future prospects.

Negatives

• The future conversion of Series D-1 Convertible Preferred Stock into common stock on June 20, 2026, will result in dilution for existing common shareholders.

Risks

• Future dilution of common stock shareholders upon the automatic conversion of Series D-1 Convertible Preferred Stock on June 20, 2026.
• Potential impact on stock price due to an increased supply of common shares in the market post-conversion.

Future Outlook

The Series D-1 Convertible Preferred Stock held by Edward Pershing will automatically convert into common stock on June 20, 2026, unless converted earlier in accordance with its terms.

Industry Context

Insider transactions, such as the conversion of debt to equity, are common in the biotechnology and pharmaceutical sectors, particularly for smaller companies like Provectus Biopharmaceuticals, where management often has significant equity stakes or provides financing. Such conversions can be part of pre-arranged financing agreements or strategic moves to strengthen the balance sheet.

Related Party Transactions

• Edward Pershing, as CEO and Director, converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, representing a transaction between a key insider and the company.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon the conversion of Series D-1 Preferred Stock into common shares.
• Creditors: Reduction in outstanding debt (the 2024 Note), which could be viewed positively.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled insider transaction involving the conversion of a convertible note into preferred stock. While it reduces debt and shows insider commitment, it also signals future dilution. Without additional fundamental company news, this filing alone does not provide sufficient information to warrant a strong buy or sell recommendation, thus a 'hold' is appropriate as investors should await broader operational or financial updates.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Form 4, insider transaction, convertible note, preferred stock, debt conversion, equity, CEO, director, 10b5-1